MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/09546634.2019.1589641

Медицинская библиотека · The Journal of dermatological treatment · 2019

Off-label studies on apremilast in dermatology: a review.

Maloney Nolan J, Zhao Jeffrey, Tegtmeyer Kyle, Lee Ernest Y, Cheng Kyle

СтатьяОбзорПеревод в очереди

Аннотация

Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication.Materials and methods: The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify published data on off-label uses of apremilast. The article was structured by the quality of evidence available.

Results

Apremilast use in dermatology beyond plaque psoriasis and psoriatic arthritis is frequently described in the literature, with a mixture of positive and negative results. Randomized controlled data is available for Behçet's disease, hidradenitis suppurativa, nail/scalp/palmoplantar psoriasis, alopecia areata, and atopic dermatitis.

Conclusion

The relatively safe adverse effect profile of apremilast and its broad immunomodulatory characteristics may make it a promising option in the future for patients with difficult to treat diseases in dermatology, refractory to first line therapies, but further studies will be necessary to clarify its role.

Для цитирования: Maloney Nolan J, Zhao Jeffrey, Tegtmeyer Kyle, Lee Ernest Y, Cheng Kyle. Off-label studies on apremilast in dermatology: a review.. The Journal of dermatological treatment. 2019. DOI: 10.1080/09546634.2019.1589641.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.